Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
Wang, Eunice S. , Montesinos, Pau , Foran, James M. , Erba, Harry P. , Rodríguez‐Arbolí, Eduardo , Fedorov, Kateryna, Heiblig, Maël , Heidel, Florian H. , Altman, Jessica K. , Baer, Maria R. , Pettit, Kristen , Papayannidis, Cristina , Walter, Roland B. , Khawandanah, Mohamad , Garcia, Olga Salamero, Bergeron, Julie , Ulrickson, Matthew L. , Redner, Robert L. , McCloskey, James, Pigneux, Arnaud , Fuente, Adolfo de la , Mitra, Amitava , Soifer, Harris S. , Tabachri, Marilyn, Zhang, Zijing , Riches, Marcie , Corum, Daniel, Leoni, Mollie , Barabé, Frédéric , Bergeron, Julie, Castillo, Teresa Bernal del, Berthon, Céline, Elsawy, Mahmoud , Reyner, Jordi Esteve, Fedorov, Kateryna, Giannini, Caterina, Heiblig, Maël, Issa, Ghayas C., Penedo, Agustín, Garcia, Olga Salamero, Ulrickson, Matthew, Venditti, Adriano , Walter, Roland B., Wang, Eunice S., Foran, James M , Erba, Harry Paul , Peterlin, Pierre , Berthon, Céline , Walter, Roland B , Shah, Mithun V , Balasubramanian, Suresh , Khawandanah, Mohamad , Bergeron, Julie , Roboz, Gail J , Ulrickson, Matthew , Pigneux, Arnaud , de la Fuente Burguera, Adolfo , Issa, Ghayas , Fathi, Amir T , Wang, Eunice S. , Montesinos, Pau , Pettit, Kristen , Papayannidis, Cristina , Heiblig, Mael , Fedorov, Kateryna, Adès, Lionel , Shah, Meera , Garcia, Olga Salamero, Madanat, Yazan F. , Roboz, Gail J. , Castillo, Teresa Bernal del, Deeren, Dries , Esteve, Jordi , Fedorov, Kateryna, Heiblig, Maël, Issa, Ghayas C., Lanza, Francesco , Garcia, Olga Salamero, Schwarzer, Adrian , Ulrickson, Matthew, Walter, Roland B., Wang, Eunice S.

Journal of Clinical Oncology | September 25, 2025 | Volume: 43 | Issue: 31 | Pages: 3381-3390

10.1200/jco-25-01694 | PMID 40997296 Get It

PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial. METHODS In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1 -m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh). RESULTS From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events. CONCLUSION Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1 -m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma
Vile, Richard G.

Journal of Clinical Oncology | September 25, 2025 | Volume: 43 | Issue: 33 | Pages: 3622-3626

10.1200/jco-25-01890 | PMID 40997291 Get It

Short-course versus long-course antibiotic treatment for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials
Fite, Amsalu, Farooqi, Mashood , Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Samreen Rizwan Ahmed, Sahra, Syeda , Torres, Antoni, Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, Nihar Yogesh, Cheema, Huzaifa Ahmad , Singh, Harpreet , Ahmad, Sharjeel , Ahmad, Faran , Torres, Antoní

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine | September 25, 2025 | Volume: 9 | Issue: 5 | Pages: 247-254

10.1080/24745332.2025.2552193 Get It

An Expanding Perspective: Extreme Aortic Dilation in a Patient With Single Ventricle Palliation
Krebushevski, Kaitlyn , Jenson, Anders C. , Amundson, Aaron A., Niaz, Talha , Pochettino, Alberto , Bonnichsen, Crystal R. , Cetta, Frank , Jenson, Anders , Bonnichsen, Crystal , Niaz, Talha , Amundson, Aaron A.

World Journal for Pediatric and Congenital Heart Surgery | September 25, 2025 | Volume: 17 | Issue: 2 | Pages: 279-282

10.1177/21501351251369448 | PMID 40997249 Get It

Aortic dilation following single ventricle palliation is increasingly recognized, although its long-term clinical implications remain unclear. We present the case of a 38-year-old male born with a bicuspid aortic valve, d-transposition of the great arteries, ventricular septal defect, right ventricular hypoplasia with a straddling right atrioventricular valve. He was palliated with Fontan circulation and developed severe neo-aortic root and arch dilation with native aortic valve stenosis, requiring surgical intervention. His neo-aortic root measured 81 × 65 mm, necessitating a Bentall procedure with total arch and native aortic valve replacement. This case underscores the variable progression of aortic dilation in patients with palliated single ventricle physiology and the need for strict surveillance and individualized management. Larger cohort studies are needed to further refine the criteria for surgical intervention in this unique population.
Genetic Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease: Is It the Chicken or the Egg?
Ortega, Victor E. , Pienaar, Elsje , Escalante, Patricio

American Journal of Respiratory and Critical Care Medicine | September 25, 2025 | Volume: 211 | Issue: 11 | Pages: 2150-2152

10.1164/rccm.202508-1970ed | PMID 40997233 Get It

Dynamic Stability Analysis of Progressive Supranuclear Palsy Affected Gait Using Lyapunov Floquet Theory
Bhat, Sandesh G. , Ali, Farwa , Hogen, Cecilia A., Rezaei, Asghar , Josephs, Keith A. , Whitwell, Jennifer L. , Bhat, Sandesh G , Whitwell, Jennifer , Kaufman, Kenton R.

IEEE Transactions on Neural Systems and Rehabilitation Engineering | September 25, 2025 | Volume: 33 | Issue: No issue available | Pages: 3958-3964

10.1109/tnsre.2025.3614555 | PMID 40997017 Get It

Fixative faux pas: glutaraldehyde’s limitation in imaging mass cytometry studies of kidney biopsies
Alexander, Mariam P., Strausbauch, Michael, Murugesan, Vidhya Dharshini , Kourelis, Taxiarchis , Taner, Timuçin , Alexander, Mariam P. , Alexander, Mariam P , Pavelko, Kevin, Pavelko, Kevin D. , McKee, Trevor D.

Journal of Clinical Pathology | September 25, 2025 | Volume: 79 | Issue: 4 | Pages: 283-285

10.1136/jcp-2025-210258 | PMID 40998575 Get It

Inhibition of lipolysis in visceral adipose tissue from obese mice and humans prevents impairment of endothelial Kir2.1 channels
Hudgins, Emma C. , Johnson, Erica J. , Rokka, Sabita, Kashyap, Bhaswati , Mahugu, Arielle, Nguyen, Thanh, Tascone, Anthony R., McCarthy, Elizabeth , Halbert, Caitlin , Fancher, Ibra S.

Channels | September 25, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1080/19336950.2025.2564651 | PMID 40996861 Get It

Approach to Ophthalmic Surgery Involving the Anterior Vitreous: A Clinical Practice Update from the American Society of Retina Specialists
Vajzovic, Lejla , Blinder, Kevin J. , Jumper, J. Michael, Starr, Matthew R , Blinder, Kevin J , Starr, Matthew R. , Weng, Christina Y. , Kim, Judy E.

Journal of VitreoRetinal Diseases | September 25, 2025 | Volume: 9 | Issue: 6 | Pages: 744-750

10.1177/24741264251376033 | PMID 41020166 Get It

When encountering diseases of the anterior vitreous and peripheral retina (ie, the “middle segment” of the eye), vitreoretinal (VR) surgeons are specifically trained in surgical techniques for managing the vitreous and visualizing the peripheral retina during anterior vitrectomy, and therefore, they are well equipped to address the complications of surgery involving the anterior vitreous space. This clinical update reviews and compares the current literature discussing techniques and patient outcomes related to complete pars plana vitrectomy versus incomplete, subtotal pars plana vitrectomy, and addresses the proposition of developing an abridged training curriculum for non-VR surgeons to acquire the knowledge and skills required to perform these procedures. Recent studies confirmed that operating in the anterior vitreous carries potential risk of retinal tear, retinal detachment, and other adverse events that may cause vision loss. To mitigate these risks, studies suggest that the use of dedicated visualization equipment and illumination instruments is necessary for surgeons to safely perform anterior vitrectomy and recognize complications, should any occur. Performing VR surgery in the absence of wide-angle viewing systems, endoillumination, careful peripheral examinations, modern vitrectomy platforms, and appropriate training may lead to outcomes that are detrimental to patient safety.
Hospital and Temporal Variations in Limitations of Care Among Hospitalized Patients with COVID-19: A VIRUS Registry Retrospective Cohort Study
Mesfin, Nathan , Jain, Nitesh , Mushtaq, Hisham, Jama, Abbas B, Attallah, Noura , Hassan, Esraa, Ingraham, Nicholas E. , Garces, Juan Pablo Domecq , Armaignac, Donna Lee , Perkins, Nicholas , Belden, Katherine , Kumar, Vishakha K. , Boman, Karen , Sanghavi, Devang , Bansal, Vikas , Cartin‐Ceba, Rodrigo , Nou, Abigail La, Dudley, R. Adams , Khan, Syed Anjum , Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): Covid-19 Registry Investigator, Koritala, Thoyaja , Sanghavi, Devang K., Khedr, Anwar , Langworthy, Benjamin , Bansal, Vikas, Kashyap, Rahul, Walkey, Allan J. , Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): Covid-19 Registry Investigator

Palliative Medicine Reports | September 25, 2025 | Volume: 6 | Issue: 1 | Pages: No page available

10.1177/26892820251380523 | PMID 41142473 Get It

Introduction: Life-support limits (i.e., code status), the first step in the continuum of palliation and end-of-life (EoL) care, stem from decisions made by patients and their providers to align care near the EoL with patients’ wishes. The pandemic created health care strain that may have influenced life-support limitation practices among patients with serious COVID-19. In this study, we examine variations in life-support limitations (do-not-resuscitate, DNR; do-not-intubate, DNI) depending on the hospital and period of hospitalization. Methods: We included all adults admitted to a hospital in the United States with COVID-19 from January 2020 to December 2021 using the VIRUS registry. Our outcome was any life-support limitation on admission (DNR, DNI, or both) using regression modeling. Main exposures were hospital and period of hospitalization (early vs. late pandemic). Covariates included age, sex, race/ethnicity, comorbidities, and hospitalization diagnoses. Results: There were 42,383 patients from 75 hospitals in the US. The median age was 63 (interquartile range: 50–75), 46.5% were female, and 37.5% were non-Hispanic White. The life-support limitation rate was 7.9%, and the palliative care consultation rate was 2.3%. The odds of life-support limitation were 1.86 (95% CI: 1.6–2.1) depending on the hospital, but the period of hospitalization was not associated with odds of life-support limitation. Older age was associated with the greatest increased odds (4.1 per standard deviation ∼ 17.9 years, 95% CI: 3.9–4.4), followed by comorbidities including paralysis (2.4, 95% CI: 1.8–3.0) and dementia (2.3, 95% CI: 2.0–2.6). Conclusions: After adjusting for patient-level factors, we report significant inter-hospital but no temporal variation in life-support limitation upon admission with COVID-19. Future studies should investigate specific practices that led to health care resilience to temporal practice variations in life-support limitation during the pandemic.